

**P0702 Efficacy and safety of darunavir-ritonavir 1200/100mg once daily for the treatment of HIV-1 Infection: DARONCE study**

Melissa Medeiros<sup>1,2</sup>, Priscyla Araripe<sup>1</sup>, Karina Noroes<sup>1</sup>, Larissa Amorim<sup>1</sup>, Yandra Mirelle Alves<sup>1</sup>, Jose Edvar Di Castro Junior<sup>1</sup>, Antonio Erisvaldo Ponte Filho<sup>1</sup>, Leticia Cristino<sup>1</sup>, Juliana Oliveira<sup>1</sup>, Kilmer Castelo Branco<sup>1</sup>, Gustavo Igor Rodrigues<sup>1</sup>, Luan Victor Lima<sup>1,2</sup>, Christianne Takeda\*<sup>2</sup>

<sup>1</sup> Medicine School, Unichristus Campus Ecological Park, Brazil, <sup>2</sup> Rua Nestor Barbosa 315, Hospital Sao Jose de Doenças Infecciosas, Brazil

**Background:** High doses of darunavir boosted with ritonavir (DRV-r 1200/100mg) once daily may have advantages related to improved adherence and reduction of RTV adverse events, and to achieve viral suppression instead of twice the dose daily in experienced patients. However, there is a need to evaluate the efficacy of viral suppression and metabolic safety related to dose adjustment due to the lack of data in the literature. In Brazil there is just 600mg of Darunavir dose and it is recommended posology twice daily. Aim to evaluate viral suppression first outcome plus hepatic and renal toxicity as second outcome with DRV-r 1200/100mg.

**Materials/methods:** Retrospective and observational study of patients using DRV-r 1200/100mg once daily, in Fortaleza/Brazil. The data were collected through files, during March to September 2018. Viral load (CV), renal function and liver enzymes were evaluated before and after the proposed regimen. Patients were previously experienced to ARV.

**Results:** A total of 327 patients were followed up. Of these, 70.34% were male (N = 230). Immunologic evaluation detected 75% (N = 195) with an initial CD4 > 350 cels/mm<sup>3</sup>, and after switch 46.27% (N = 31) increased CD4; Meanwhile, 67.7% (N = 174) presented initial CV <40 copies and in the last exam 74.6% (N = 134). In addition, 50.2% (N = 164) had renal function tests and liver enzymes before and after the introduction of the regimen. It was observed that the urea before the switch was altered in 6.8% (N = 9) and after it was 7.3% (N = 10), (p = 1). Otherwise, creatinine was altered in 7.7% (N = 12) before switch and after in 6.0% (N = 9), (p = 0.6531). When assessing hepatic toxicity, the initial AST was altered by 12.9% (N = 20) and afterwards by 16.1% (N = 24), (p = 0.5147). As for ALT, previous switch it was altered in 17.5% (N = 27) and in the post in 20.3% (N = 30), (p = 0.5597).

**Conclusions:** DRV-r 1200/100mg once daily evidenced high efficacy in viral suppression and safety, proving to be a viable option to achieve undetectable CV without causing toxicity.

